Form 4: Precision BioSciences CFO Exercises Stock Options and Receives Restricted Stock Units
SEC Form 4 Filing
Precision BioSciences' Chief Financial Officer, John Alexander Kelly, exercised stock options and received restricted stock units on January 20, 2025, resulting in changes to his beneficial ownership.
Summary
- John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, Inc., engaged in transactions involving the company's stock on January 20, 2025.
- These transactions included the vesting and settlement of 44,368 Restricted Stock Units (RSUs), which converted into common stock.
- Additionally, Mr. Kelly received 3,889 RSUs from a grant on January 20, 2023, 13,904 RSUs from a grant on April 18, 2024, and 26,575 RSUs from a grant on August 22, 2024, all of which vested on January 20, 2025.
- Following these transactions, Mr. Kelly's direct ownership includes 84,554 shares of common stock and 84,839 RSUs.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and does not indicate any positive or negative sentiment. It is a routine filing.
Positives
- The vesting of RSUs indicates that Mr. Kelly has met the service requirements for these grants.
- The increase in share ownership aligns the CFO's interests with those of the shareholders.
Industry Context
This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the ownership changes of key executives.
Comparison to Industry Standards
- Stock-based compensation, including RSUs, is a standard practice in the biotechnology industry to attract and retain talent.
- The vesting schedules described are typical for executive compensation packages, often with multi-year vesting periods.
- Similar filings are regularly made by executives at comparable companies such as CRISPR Therapeutics and Editas Medicine, reflecting similar compensation structures.
Stakeholder Impact
- The transactions do not have a direct impact on stakeholders other than the CFO.
- The increase in the CFO's share ownership aligns his interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/20/2023 | Date of initial RSU grant that vested partially on 01/20/2025. |
| 04/18/2024 | Date of initial RSU grant that vested partially on 01/20/2025. |
| 08/22/2024 | Date of initial RSU grant that vested partially on 01/20/2025. |
| 01/20/2025 | Date of RSU vesting and stock option exercise. |
| 01/22/2025 | Date of filing of the SEC Form 4. |
Keywords
Precision BioSciences, stock options, restricted stock units, RSUs, beneficial ownership, insider trading, SEC Form 4, John Alexander Kelly, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.